Trial Profile

Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REGN 5459 (Primary)
Indications Multiple myeloma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Regeneron Pharmaceuticals

Most Recent Events

07 Nov 2024 Planned End Date changed from 25 Nov 2025 to 24 Nov 2025.
07 Nov 2024 Planned primary completion date changed from 22 Aug 2025 to 12 Nov 2025.
07 Jul 2023 Planned End Date changed from 27 Nov 2023 to 25 Nov 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com